论文部分内容阅读
目的:比较含吡喃阿霉素(CTOP)和表阿霉素(CEOP)的方案治疗非霍奇金淋巴瘤的疗效和毒副作用。方法:238例非霍奇金淋巴瘤患者分别接受CTOP和CEOP方案治疗, 每3周为1周期, 最少治疗3周期。结果:CTOP组和CEOP组的完全缓解率分别为46.1 %、44.5 %。总有效率(CR+PR)分别为85.9 %、82.7 %。两组的完全缓解率和总有效率经统计学分析,均无显著性差异(P>0.05)。两组的骨髓、胃肠道、血液和心脏毒性,均无统计学上的差异。脱发发生率分别为31.3 %、62.7 %,CTOP组明显低于CEOP组,两组有显著性差异。结论:CTOP与CEOP相比,疗效相近,脱发反应较轻,远期疗效有待观察。
OBJECTIVE: To compare the efficacy and toxicities of non-Hodgkin’s lymphoma with pirarubicin (CTOP) and epirubicin (CEOP). Methods: Two hundred thirty-eight non-Hodgkin’s lymphoma patients underwent CTOP and CEOP regimens respectively, with one cycle every 3 weeks and at least 3 cycles. Results: The complete remission rates of CTOP group and CEOP group were 46.1% and 44.5% respectively. The total effective rate (CR + PR) were 85.9%, 82.7%. The two groups of complete remission rate and total effective rate by statistical analysis, no significant difference (P> 0.05). There was no statistical difference between the two groups in bone marrow, gastrointestinal tract, blood and cardiotoxicity. Hair loss rates were 31.3%, 62.7%, CTOP group was significantly lower than CEOP group, the two groups were significantly different. Conclusion: Compared with CEOP, CTOP has similar curative effect and less hair loss response. The long-term curative effect remains to be seen.